

ADDTP: Rs 1,600 | ▲ 9%

NIIT TECHNOLOGIES

IT Services

24 October 2019

Solid Q2; cut to ADD on full valuations

NIIT Tech (NITEC) reported organic revenue growth of 4.1% QoQ CC and EBITDA margins of 18.3% in Q2FY20, marking a better-than-expected operating performance. Deal wins and executable order book were healthy. Optimistic BFSI commentary and expectations of normal furloughs make for a stark contrast to the outlook put out by peers. We tweak FY21/FY22 EPS and roll forward to a revised Sep'20 TP of Rs 1,600 (vs. Rs 1,550). Current valuations look full at 16.8x/14.4x FY21E/FY22E P/E – cut from BUY to ADD.

Ruchi Burde research@bobcaps.in

Operating beat: NITEC reported an above-expected operating performance as both revenues as well as margins came in a tad ahead of estimates. Revenues at US\$ 148.7mn increased 7.3% QoQ, backed by healthy organic growth (+4.1% QoQ CC). EBITDA margins at 18.3% expanded by 380bps QoQ on reported basis and by 140bps QoQ adjusted for one-off expenses in the previous quarter.

Deal wins and executable orders continue to trend up: Fresh order intake at US\$ 176mn rose for the ninth straight quarter, supported by strong deal wins in RoW at US\$ 70mn. The 12-month executable order book stood at US\$ 405mn (+11.6% YoY), rising for the eighth quarter in a row.

Optimistic BFSI commentary: Unlike peers, NITEC did not allude to secular weakness in the BFSI vertical, though management does expect growth to moderate in the Dec'19 quarter on seasonal weakness.

Valuations full: Current valuations at 16.8x/14.4x FY21E/FY22E P/E leave little upside, leading us to downgrade the stock to ADD from BUY. On rolling valuations forward, we have a revised Sep'20 TP of Rs 1,600 (vs. Rs 1,550).

Ticker/Price	NITEC IN/Rs 1,469
Market cap	US\$ 1.3bn
Shares o/s	62mn
3M ADV	US\$ 7.5mn
52wk high/low	Rs 1,545/Rs 1,031
Promoter/FPI/DII	31%/42%/27%
c NCE	

Source: NSE

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	29,914	36,762	41,264	46,377	52,154
EBITDA (Rs mn)	5,012	6,453	7,273	8,486	9,543
Adj. net profit (Rs mn)	2,802	4,089	4,469	5,395	6,295
Adj. EPS (Rs)	45.4	66.2	72.3	87.3	101.9
Adj. EPS growth (%)	3.5	45.9	9.3	20.7	16.7
Adj. ROAE (%)	15.3	21.2	20.2	21.3	21.5
Adj. P/E (x)	32.4	22.2	20.3	16.8	14.4
EV/EBITDA (x)	17.4	13.5	11.5	9.5	8.0



FIG 1 – SEP'19 QUARTER PERFORMANCE

(Rs mn)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Y ₀ Y (%)	Q ₀ Q (%)	H1FY19	H1FY20	Y ₀ Y (%)
Revenue (US\$ mn)	124.3	130.9	134.8	138.0	138.5	148.7	13.6	7.3	255.2	287.2	12.5
Revenue (Rs mn)	8,249	9,074	9,717	9,722	9,627	10,385	14.4	7.9	17,323	20,012	15.5
Operating Expenditure	6,942	7,440	7,912	8,015	8,238	8,487	14.1	3.0	14,382	16,725	16.3
Cost of revenues	5,437	5,897	6,280	6,293	6,374	6,796	15.2	6.6	11,334	13,170	16.2
as % of sales	65.9	65.0	64.6	64.7	66.2	65.4	-	-	65.4	65.8	-
SG&A expenses	1,505	1,543	1,632	1,722	1,864	1,691	9.6	(9.3)	3,048	3,555	16.6
as % of sales	18.2	17.0	16.8	17.7	19.4	16.3	-	-	17.6	17.8	-
EBITDA	1,307	1,634	1,805	1,707	1,389	1,898	16.2	36.6	2,941	3,287	11.8
Depreciation	312	319	314	303	401	447	40.1	11.5	631	848	34.4
EBIT	995	1,315	1,491	1,404	988	1,451	10.3	46.9	2,310	2,439	5.6
Other Income	210	215	4	47	172	76	-	-	425	248	-
PBT	1,205	1,530	1,495	1,451	1,160	1,527	(0.2)	31.6	2,735	2,687	(1.8)
Total Tax	300	363	445	296	318	276	(24.0)	(13.2)	663	594	(10.4)
Adjusted PAT	905	1,167	1,050	1,155	842	1,251	7.2	48.6	2,072	2,093	1.0
(Profit)/loss from JV's/Ass/MI	46.0	49.0	49.0	44.0	22.0	56.0	-	-	95	78	-
APAT after MI	859	1,118	1,001	1,111	820	1,195	6.9	45.7	1,977	2,015	1.9
Extraordinary items	0	0	0	0	57	0	-	-	0	57	-
Reported PAT	859	1,118.00	1,001	1,111	877	1,195	6.9	36.3	1,977	2,072	4.8
Reported EPS	13.9	18.1	16.2	18.0	13.3	19.3	6.9	45.7	32	33	1.9
Margins (%)							(bps)	(bps)			(bps)
EBITDA	15.8	18.0	18.6	17.6	14.4	18.3	27	385	17.0	16.4	(55)
EBIT	12.1	14.5	15.3	14.4	10.3	14.0	(52)	371	13.3	12.2	(115)
EBT	14.6	16.9	15.4	14.9	12.0	14.7	(216)	265	15.8	13.4	(236)
PAT	10.4	12.3	10.3	11.4	9.1	11.5	(81)	240	11.4	10.1	(134)
Effective Tax rate	24.9	23.7	29.8	20.4	27.4	18.1	(565)	(934)	24.2	22.1	(213)

FIG 2 - SEP'19 QUARTER OPERATING METRICS

Particulars	Q2FY20 (% Contr. to Revenue)	Q ₀ Q (%)	Y ₀ Y (%)
Revenue by Geography			
North America	49	7.9	14.4
Europe	37	14.0	24.5
RoW	37	(5.6)	(5.7)
Revenue by Vertical			
Banking and Financial Services	17	14.6	21.6
Insurance	31	15.3	22.3
Transportation	28	7.9	18.7
Manufacturing & Retail	24	(4.1)	(1.9)
Revenue Mix			
Offshore	34	7.9	8.1
Onsite	66	7.9	18.0
Client Concentration			
Тор 5	29	15.9	18.5
Non-Top 5	71	4.9	12.9



Particulars	Q2FY20 (% Contr. to Revenue)	Q ₀ Q (%)	Y ₀ Y (%)
Top 10	39	7.9	11.6
Тор 20	52	5.8	10.2
Non-Top 20	48	10.2	19.4
Digital Revenues	38	20.0	54.1
Number of Employees	10,800	503	775
Attrition (%)	12.3	(60bps)	150bps
DSO	73 days	6 days	0 days

	Q2FY20	Q1FY20	Q2FY19
Significant New Customer Addition			
USA	7	5	5
Europe	1	3	3
ROW	2	3	2
Total	10	11	10
Fresh Order Intake (US\$ mn)			
USA	65	100	86
Europe	41	58	39
ROW	70	17	35
Total	176	175	160
Executable orders over next 12M (US\$ mn)	405	395	363



Valuation methodology

Post the Sep'19 quarter results, we marginally lower FY21/FY22 EPS estimates by 1% each. Rolling valuations forward, we have a revised Sep'20 target price of Rs 1,600(vs. Rs 1,550 earlier), based on an unchanged one-year forward P/E multiple of 17x. Even as we acknowledge the company's efforts toward predictable and profitable growth, we believe current valuations at 16.8x/14.4x FY21E/FY22E P/E leave limited upside potential – cut from BUY to ADD.

FIG 3 - REVISED ESTIMATES

(Rs mn) -		FY20E			FY21E			FY22E	
(KS MN) —	Olq	New	Change (%)	Old	New	Change (%)	Olq	New	Change (%)
Revenues (US\$ mn)	597	591	(1.1)	669	663	(1.0)	753	745	(1.0)
YoY growth (%)	13.1	11.9	-	12.1	12.1	-	12.4	12.5	-
Revenues	41,275	41,264	0.0	46,864	46,377	(1.0)	52,679	52,154	(1.0)
EBITDA	7,311	7,273	(0.5)	8,574	8,486	(1.0)	9,639	9,543	(1.0)
EBITDA margins (%)	17.7	17.6	-	18.3	18.3	-	18.3	18.3	-
Net Profits	4,472	4,469	(0.1)	5,462	5,395	(1.2)	6,369	6,295	(1.2)
EPS (Rs)	72.4	72.3	(0.1)	88.4	87.3	(1.2)	103.1	101.9	(1.2)

Source: BOBCAPS Research

FIG 4 - RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

Downside risks to our earnings estimates include:

- challenges at the company's top clients,
- unfavourable US visa and immigration regulation changes,
- a sharp decline in demand, and
- adverse currency movement.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue	29,914	36,762	41,264	46,377	52,154
EBITDA	5,012	6,453	7,273	8,486	9,543
Depreciation	1,273	1,248	1,697	1,798	1,944
EBIT	3,739	5,205	5,576	6,687	7,599
Net interest income/(expenses)	0	0	0	0	0
Other income/(expenses)	298	476	600	936	1,216
Exceptional items	0	0	0	0	0
EBT	4,037	5,681	6,176	7,623	8,815
Income taxes	950	1,404	1,449	1,868	2,160
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	285	188	258	360	360
Reported net profit	2,802	4,089	4,469	5,395	6,295
Adjustments	0	0	0	0	0
Adjusted net profit	2,802	4,089	4,469	5,395	6,295

Balance Sheet

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Accounts payables	0	0	0	0	0
Other current liabilities	5,115	6,345	7,122	8,005	9,002
Provisions	2,943	3,626	4,070	4,574	5,144
Debt funds	224	224	224	224	224
Other liabilities	455	455	455	455	455
Equity capital	615	615	615	615	615
Reserves & surplus	17,348	20,001	22,953	26,566	30,721
Shareholders' fund	17,963	20,616	23,568	27,181	31,336
Total liabilities and equities	26,700	31,266	35,440	40,439	46,161
Cash and cash eq.	4,102	7,102	10,665	14,977	19,966
Accounts receivables	5,911	7,352	8,253	9,275	10,431
Inventories	0	0	0	0	0
Other current assets	2,701	3,324	3,731	4,193	4,715
Investments	3,955	3,955	3,955	3,955	3,955
Net fixed assets	8,800	8,302	7,605	6,807	5,863
CWIP	7	7	7	7	7
Intangible assets	0	0	0	0	0
Deferred tax assets, net	1,231	1,231	1,231	1,231	1,231
Other assets	0	0	0	0	0
Total assets	26,700	31,266	35,440	40,439	46,161



Cash Flows

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net income + Depreciation	4,199	5,525	6,424	7,554	8,599
Interest expenses	(34)	(476)	(600)	(936)	(1,216)
Non-cash adjustments	0	0	0	0	0
Changes in working capital	(128)	(151)	(86)	(98)	(111)
Other operating cash flows	(213)	0	0	0	0
Cash flow from operations	3,824	4,898	5,737	6,520	7,272
Capital expenditures	(879)	(750)	(1,000)	(1,000)	(1,000)
Change in investments	(290)	0	0	0	0
Other investing cash flows	(1,311)	476	600	936	1,216
Cash flow from investing	(2,480)	(274)	(400)	(64)	216
Equities issued/Others	66	0	0	0	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	0	0	0	0	0
Dividends paid	(810)	(1,624)	(1,775)	(2,143)	(2,500)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(744)	(1,624)	(1,775)	(2,143)	(2,500)
Changes in cash and cash eq.	600	3,000	3,563	4,313	4,988
Closing cash and cash eq.	4,102	7,102	10,665	14,977	19,966

Per Share

Y/E 31 Mar (Rs)	FY18A	FY19A	FY20E	FY21E	FY22E
Reported EPS	45.4	66.2	72.3	87.3	101.9
Adjusted EPS	45.4	66.2	72.3	87.3	101.9
Dividend per share	15.0	21.8	23.9	28.8	33.6
Book value per share	290.8	333.7	381.5	440.0	507.2

Valuations Ratios

Y/E 31 Mar (x)	FY18A	FY19A	FY20E	FY21E	FY22E
EV/Sales	2.9	2.4	2.0	1.7	1.5
EV/EBITDA	17.4	13.5	11.5	9.5	8.0
Adjusted P/E	32.4	22.2	20.3	16.8	14.4
P/BV	5.1	4.4	3.8	3.3	2.9

DuPont Analysis

Y/E 31 Mar (%)	FY18A	FY19A	FY20E	FY21E	FY22E
Tax burden (Net profit/PBT)	69.4	72.0	72.4	70.8	71.4
Interest burden (PBT/EBIT)	108.0	109.1	110.8	114.0	116.0
EBIT margin (EBIT/Revenue)	12.5	14.2	13.5	14.4	14.6
Asset turnover (Revenue/Avg TA)	116.5	126.8	123.7	122.2	120.4
Leverage (Avg TA/Avg Equity)	1.4	1.5	1.5	1.5	1.5
Adjusted ROAE	15.3	21.2	20.2	21.3	21.5
6 6 80804868	I I N I TA	T 1 A			

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
YoY growth (%)					
Revenue	7.4	22.9	12.2	12.4	12.5
EBITDA	6.9	28.8	12.7	16.7	12.5
Adjusted EPS	3.5	45.9	9.3	20.7	16.7
Profitability & Return ratios (%)					
EBITDA margin	16.8	17.6	17.6	18.3	18.3
EBIT margin	12.5	14.2	13.5	14.4	14.6
Adjusted profit margin	9.4	11.1	10.8	11.6	12.1
Adjusted ROAE	15.3	21.2	20.2	21.3	21.5
ROCE	12.6	18.1	20.0	25.2	30.4
Working capital days (days)					
Receivables	66	66	69	69	69
Inventory	0	0	0	0	0
Payables	107	132	127	128	129
Ratios (x)					
Gross asset turnover	3.5	4.3	5.2	6.4	8.2
Current ratio	1.6	1.8	2.0	2.3	2.5
Net interest coverage ratio	NA	NA	NA	NA	NA
Adjusted debt/equity	(0.2)	(0.3)	(0.4)	(0.5)	(0.6)



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: NIIT TECHNOLOGIES (NITEC IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 30 September 2019, out of 77 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 47 have BUY ratings, 15 are rated ADD, 6 are rated REDUCE and 9 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

NIIT TECHNOLOGIES



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.